Immunizing female mice with a Zika vaccine can protect their developing fetus from infection and birth defects during pregnancy, according to new research from The University of Texas Medical Branch at Galveston. The findings are now available in Cell.
Although rapid and promising progress on developing vaccines has been made with animal models, the UTMB study is the first to demonstrate that potential vaccines could protect a fetus from the Zika virus.
“In the study, we were the first to show that two different potential vaccines given to the mother prevent the Zika virus from infecting the fetus during pregnancy in a mouse model,” said UTMB’s Pei-Yong Shi, senior author and the I.H. Kempner professor at the Department of Biochemistry and Molecular Biology. “Based on these data, we believe that evaluating the vaccines’ ability to prevent birth defects in humans is warranted.”
While a Zika infection typically results in mild or symptom-free infections in healthy adults and children, the risk of microcephaly and other diseases in a developing fetus is an alarming consequence that has created a worldwide health threat. Pregnant women who are infected with the Zika virus but never display any disease symptoms may still give birth to a baby with microcephaly.
Female mice were vaccinated against Zika with one of the two developing vaccines prior to becoming pregnant and then exposed to the virus during their pregnancies. Shi and colleagues found the vaccinated pregnant mice showed little or no evidence of the virus in the mothers’ body including the placenta or in the fetuses’ bodies.
“Having a Zika vaccine that can protect pregnant women and their unborn babies would improve public health efforts to avoid birth defects and other effects of the disease in regions where Zika is circulating,” Shi said.
Other authors include UTMB’s Chao Shan, Camila Fontes, Bruno Nunes, Daniele Medeiros, Antonio Muruato, Huanle Luo, Tian Wang, Alan Barrett, Scott Weaver and Shannan Rossi; Justin Richner, Brett Jagger, Bin Cao, Elizabeth Caine and Indira Mysorekar from Washington University School of Medicine; Kimberly Dowd, Bryant Foreman and Theodore Pierson from the National Institutes of Health; Sunny Himansu and Giuseppe Ciaramella from Valeria LLC, a Moderna Venture as well as Pedro Vasconcelos from Evandro Chagas Institute, Ministry of Health, Parå State University, Brazil.
This work was supported by the National Institutes of Health, the Defense Advances Research Projects Agency, the Burroughs Wellcome Fund, the March of Dimes, Moderna, UTMB, The University of Texas System, the Pan American Health Organization, the Ministry of Health of Brazil, the Brazilian Agency for Scientific and Technological Development and the Coordination of Professionals of High Level Degree of Ministry of Education of Brazil.
ABOUT UTMB HEALTH: Texas' first academic health center opened its doors in 1891 and today has three campuses, four health sciences schools, three institutes for advanced study, a research enterprise that includes one of only two national laboratories dedicated to the safe study of infectious threats to human health, a Level 1 Trauma Center and a health system offering a full range of primary and specialized medical services throughout Galveston County and the Texas Gulf Coast region. UTMB Health is an institution in the University of Texas System and a member of the Texas Medical Center.